Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Absolutely Publican.
The money is made with patience; my first real success was ITM… Clearly about 4 years early but an average of about 13p before it took off… Thought I was clever selling at £1, thought it was fully valued at a billion before continued north to a valuation of several billions… (On little actual revenue and with the same bafoons managing the company).
Run the winners… But don’t be too greedy.
No denial of Sony relationship this am… Augers well IMO. If it was rubbish they would likely be forced to say.
Bongs,
Enjoyed your thoughts… My cheeky one is Bids mount reverse takeover of Azerion! ??
Yes soon to be the most populous country in the world…
What would be interesting in the likely forthcoming trading update would be a comparative ‘global reach’ figure… Must be many multiples of where they were even 6 months ago.
Hint, Hint Bids….
Very well put Bottmz,
‘...the point where Bids offering becomes a no brainer for big players, publishers, brands, agencies etc, to adopt what Bids are offering.’
It’s pretty clear from all the partnerships with massive global players that this is taking place - so often they don’t even RNS the events..
No chartist either, but agree with what you have written… Lots of ‘green’ stocks look similar (eg eqt).. Just a matter of time/ news….Shame the latest statement had no component of investment just tax rises!
Though to be fair later in the article this particular partnership suggests ‘only’ 300mil monthly active users between 4-24 years old…
Hopefully a trading update will soon confirm significant revenue traction, but it’s the forward trading statement that going to be the key driver I suspect.
Yes that caught my eye… Coming from the company itself!
I’m sure Draper has his price… I certainly do!
Couldn’t put it better Bottomz, only to add one of the very major companies Bids are currently dealing with, with mcaps in the billions will look at Bids soon and snap it up for a song… (likely multiples of where the sp is now, but still a tiny sum when viewed against potential…)
Flaming Sambucca’s - Bids only slightly damned by Adebran’s faint praise!
As I alluded to below taken a bit of time to achieve likely exponential growth but looking on the box seat now with a somewhat ridiculous valuation all that considered… Plenty of evidence posted of ads in game… Plenty more platforms where the ad penetration will increase further… Cash for some time with an industry leader taking a stake.
Lots of ducks ffs
Yes Bottomz, Stan seems to be now desperate de-ramper rather than stale bull, (for which I have some sympathy), even though what they post is self defeating….
Well you know Stan we all fallen for hype and profit projections before a share is really going to take off. It’s why AIM investing is difficult, finding the wheat in a lot of chaff. Happy to admit I was a year early here… But the decision to buy was mine (and yours) alone - you can’t blame Draper for that.
If the company now is a third of the SP it was when you bought and the prospects, product and potential three times what it was then (backed up by some evidence), I would say you just need to sit tight… Or dare I say buy a load more!
‘Terrible raise’ at the current market price with a large investor. What would you like - 20% discount? No doubt that would have helped your agenda.
It’s pretty clear the business has started to reach escape velocity. Do you have the cajones to invest before the crowd? Unlikely.
It is interesting there is little movement with these deals which may collectively be worth more than the Azerion deal… But don’t come with the ‘Euro30m’ cachet but certainly may be worth similar or more to Bids in the medium
term.
‘I think when it comes to clinicians, they use the tools available to them don't they? These people are doers as well as thinkers but ultimately they make decisions. So the mentality is quite different in many ways to a drug developer.’
Bojo, if I may…
Clinicians will use the best resources made available, in the U.K. regardless of cost (as spelt out in the GMC ‘Duties of a Doctor’). Expensive drug use is restricted to ‘clinically proven’ indications which may stipulate a certain pathological threshold (eg PDL1 status for immunotherapy) by NHS England (or equivalent). If parsortix helps to improve prediction of drug response rates or is good at monitoring response more accurately than scans (often very difficult with immunotherapy) then it would be very quickly adopted in the U.k… Because treatment costs £10k/month. You don’t need to stop very many treatment for that to save millions/billions.
There also needs to be a simple test. You can’t send samples on many patients to too many different places before it’s impossible to lose track… And often stepwise tests are required (eg Her-2 status and if negative moving onto PDL1 CPS score for oesophagus cancer - both done in the same lab, and unsurprisingly therefore they get all the business).
My impression is the US is different (I think clinicians may still even get commission from pharma!) but insurance reimbursement codes would follow when clear cost utility is demonstrated though market leaders can probably start before these are available. I think it’s probably more open to money distorting clinical priorities but I have no direct experience. Certainly the private health sector in the U.K. works that way.